|
Crystalloid therapy
|
|
Number of patients
|
26 (100%)
|
32 (100%)
| |
>.99
|
|
Total volume (mls)
|
1250 (1000 to 2025)
|
2000 (1725 to 3150)
|
-799 (−1414 to − 186)b
|
0.007
|
|
Colloid therapy (excluding blood)
|
|
Number of patients
|
17 (65%)
|
18 (56%)
| |
0.59
|
|
Total volume (mls)
|
500 (200 to 1000)
|
750 (500 to 1000)
|
−105 (− 173.7 to 382.8)
|
0.41
|
|
Colloid type
|
|
4% albumen (no of patients)
|
11 (42%)
|
15 (47%)
| |
0.79
|
|
Total volume (mls)
|
1000 (500:1000)
|
1000 (500:1000)
| | |
|
20% albumen (no of patients)
|
6 (23%)
|
3 (9%)
| |
0.27
|
|
Total volume (mls)
|
200 (100:200)
|
200 (100:200)
| | |
|
Total fluids (including colloids, crystalloids and blood) (mls)
|
2000 (1175 to 2700)
|
2750 (2000 to 4000)
|
−729 (−1462 to −3.03)a
|
0.026
|
|
Blood transfusion (number of patients)
|
3 (11.5%)
|
2 (6.2%)
| |
0.4
|
|
Total volume (ml)
|
465 (465:1000)
|
1275 (1275:1400)
| | |
|
Urine output (ml)
|
220 (155 to 300)
|
320 (195 to 485)
| |
0.022
|
|
Blood loss (ml)
|
400 (300 to 950)
|
400 (300 to 750)
|
17.0 (−201 to 235)b
|
0.61
|
|
Fluid balance
|
1215 (613 to 1680)
|
2095 (1330 to 3608)
|
−921 (−1646 to −196)b
|
0.005
|
|
Number of patients receiving a vasoactive medication
|
20 (77%)
|
29 (91%)
|
0.23 (0.04 to 1.1) c
|
0.12
|
|
Metaraminol use (number of patients)
|
6 (23%)
|
23 (72%)
|
0.12 (0.04 to 0.37)c
|
< 0.001
|
|
Metaraminol (mg)
|
0 (0–1)
|
3 (0–9)
|
−3.64 (−5.82 to −1.46)b
|
< 0.005
|
|
Ephedrine/dopamine use (number of patients)
|
3 (12%)
|
8 (25%)
|
0.39 (0.10 to 1.61)c
|
0.31
|
|
Epinephrine (mg)
|
0 (0–0)
|
0 (0–8)
|
4.56 (−9.50 to 0.38)b
|
0.08
|
|
Noradrenaline use (number of patients)
|
15 (46%)
|
9 (28%)
|
3.49 (1.23 to 9.47) c
|
0.03
|
|
Noradrenaline (ug)
|
390 (0 to 870)
|
0 (0 to 353)
|
1.67 (− 325 to 662)b
|
0.10
|
